ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 176 filers reported holding ASCENDIS PHARMA A/S in Q4 2020. The put-call ratio across all filers is 1.39 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $11,611 | -21.2% | 124 | -24.8% | 0.00% | – |
| Q2 2023 | $14,726 | -33.0% | 165 | -19.5% | 0.00% | – |
| Q1 2023 | $21,980 | -94.2% | 205 | -95.0% | 0.00% | -100.0% |
| Q2 2022 | $380,000 | -20.8% | 4,093 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $480,000 | -12.9% | 4,093 | 0.0% | 0.00% | -33.3% |
| Q4 2021 | $551,000 | -15.5% | 4,093 | 0.0% | 0.00% | -25.0% |
| Q3 2021 | $652,000 | +21.2% | 4,093 | 0.0% | 0.00% | +33.3% |
| Q2 2021 | $538,000 | -13.6% | 4,093 | -15.4% | 0.00% | -25.0% |
| Q1 2021 | $623,000 | -22.8% | 4,837 | 0.0% | 0.00% | -20.0% |
| Q4 2020 | $807,000 | +29.1% | 4,837 | +19.4% | 0.01% | +25.0% |
| Q3 2020 | $625,000 | +4.3% | 4,052 | 0.0% | 0.00% | -20.0% |
| Q2 2020 | $599,000 | +90.8% | 4,052 | +45.5% | 0.01% | +66.7% |
| Q1 2020 | $314,000 | -18.9% | 2,785 | 0.0% | 0.00% | 0.0% |
| Q4 2019 | $387,000 | – | 2,785 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 5,909,742 | $911,991,000 | 16.68% |
| Vivo Capital, LLC | 1,797,745 | $277,428,000 | 16.03% |
| Sofinnova Investments, Inc. | 1,109,874 | $171,276,000 | 12.70% |
| Asymmetry Capital Management, L.P. | 81,442 | $12,568,000 | 8.08% |
| Ghost Tree Capital, LLC | 130,000 | $20,062,000 | 5.80% |
| Eversept Partners, LP | 161,004 | $24,846,137 | 5.52% |
| Eventide Asset Management | 1,709,848 | $263,864,000 | 5.16% |
| Avoro Capital Advisors LLC | 1,800,000 | $277,776,000 | 3.95% |
| BERYLSON CAPITAL PARTNERS, LLC | 72,700 | $11,219,000 | 3.93% |
| Spyglass Capital Management LLC | 547,022 | $84,416,000 | 3.90% |